Opportunity Information: Apply for W81XWH 12 PCRP SIDA
Apply for W81XWH 12 PCRP SIDA
- The Dept. of the Army USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Prostate Cancer Synergistic Idea Development Award" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420 Military Medical Research and Development.
- This funding opportunity was created on Mar 20, 2012 and posted on Mar 20, 2012.
- Applicants must submit their applications by Aug 9, 2012. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The funding agency has allocated a total of $6,000,000.00 to eligible and selected applicants.
- The number of recipients for this funding is limited to 5 candidate(s).
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The DoD Prostate Cancer Synergistic Idea Development Award (Funding Opportunity Number W81XWH-12-PCRP-SIDA) is a U.S. Department of the Army (USAMRAA) funding opportunity under the Congressionally Directed Medical Research Programs (CDMRP) that supports collaborative, research-driven efforts aimed at making meaningful advances in prostate cancer. It is designed specifically to fund projects where the main value comes from true collaboration and combined expertise, rather than from a single investigator working alone. The award mechanism can be issued as either a grant or a cooperative agreement, and it falls under the Science and Technology / Research and Development activity category.
A key feature of this opportunity is its two-step submission process: a preproposal is required first, and only those invited after the preproposal stage are allowed to submit a full application. In practical terms, that means investigators cannot submit a full proposal unless they are formally invited, so the preproposal becomes the critical gatekeeping step. The program expects to make about five awards, with an estimated total funding pool of $6,000,000. No cost sharing or matching funds are required. Eligibility is broadly open (unrestricted) to any type of entity, as long as the applicant meets any additional eligibility details specified in the full announcement.
The award is built to support either new partnerships or existing collaborations, but the partnership structure is specific: proposals must involve two or three independent investigators working together. The purpose of this team requirement is to push synergistic science, meaning the combined team should be capable of producing ideas, approaches, or outcomes that would not be achievable if the investigators were working separately. The research must revolve around a central innovative question or problem in prostate cancer, and the program allows for high-risk concepts as long as there is a credible possibility of major impact. This emphasis signals that the funder is willing to consider bold or unconventional directions, provided the rationale is strong and the potential payoff is significant.
In terms of application expectations, preliminary data are encouraged but not required. This is important because it lowers the barrier for newer ideas or emerging collaborations that may not yet have extensive supporting datasets. Even so, the proposal is still expected to be rigorous and persuasive about why the approach is innovative, why the team is uniquely positioned to tackle the problem, and how the work could materially change understanding, prevention, diagnosis, or treatment strategies related to prostate cancer.
The most important review criteria for this award are Synergy, Innovation, and Impact. Synergy focuses on whether the collaboration is real and necessary, including how the investigators integrate their expertise, share responsibilities, and create added value through partnership. Innovation looks at how novel the concepts, hypotheses, methods, or technologies are, and whether the project challenges existing assumptions or opens new pathways in the field. Impact centers on the likelihood that the project will significantly advance prostate cancer research or lead to meaningful downstream benefits. These criteria collectively indicate that the program is not primarily seeking incremental progress, but rather research that could move the needle in a noticeable way.
A major restriction is that the award does not support clinical trials. Projects should therefore be scoped to preclinical, translational, mechanistic, computational, biomarker discovery/validation (as long as it is not structured as a clinical trial), or other non-clinical-trial research activities that can still drive substantial advances. Applicants need to ensure their proposed aims, endpoints, and study design do not cross into clinical trial territory as defined by the funder.
The opportunity was posted on March 20, 2012, with an original and final closing date of August 9, 2012, and it was archived on September 8, 2012. For technical access issues with the full announcement, the contact listed is the CDMRP Help Desk at 301-682-5507.
FAQs: DoD Prostate Cancer Synergistic Idea Development Award (W81XWH-12-PCRP-SIDA)
What is the DoD Prostate Cancer Synergistic Idea Development Award?
It is a U.S. Department of the Army (USAMRAA) funding opportunity under the Congressionally Directed Medical Research Programs (CDMRP) that supports collaborative, research-driven projects intended to make meaningful advances in prostate cancer. The mechanism is built around true scientific synergy, where the main value comes from investigators combining expertise rather than working independently.
What is the Funding Opportunity Number (FON) for this award?
The Funding Opportunity Number is W81XWH-12-PCRP-SIDA.
Which agency and program sponsor this opportunity?
The opportunity is offered through the U.S. Department of the Army (USAMRAA) under the Congressionally Directed Medical Research Programs (CDMRP).
What type of funding instrument is used?
The award mechanism can be issued as either a grant or a cooperative agreement.
What activity category does this award fall under?
It falls under the Science and Technology / Research and Development activity category.
What is the overall purpose of this award?
The award is designed to fund collaborative projects centered on an innovative prostate cancer question or problem, with an emphasis on synergy, innovation, and the potential for major impact.
How many investigators must be involved in a proposal?
Proposals must include two or three independent investigators working together as a collaboration team.
Are single-investigator projects allowed?
No. This mechanism is specifically intended for projects where the core value comes from collaboration among two or three independent investigators.
Can the collaboration be a new partnership, or does it need to be established?
Both are allowed. The award supports either new partnerships or existing collaborations, as long as the project is structured around genuine synergy among the investigators.
What does "synergy" mean in the context of this award?
Synergy refers to a collaboration where the investigators integrate expertise and responsibilities in a way that creates added scientific value. The expected outcome is that the team can generate ideas, approaches, or results that would not be achievable if each investigator worked separately.
What is the application process?
This opportunity uses a two-step submission process. A preproposal is required first, and only applicants who are invited after the preproposal stage may submit a full application.
Can an applicant submit a full proposal without an invitation?
No. Investigators may only submit a full application if they are formally invited following the preproposal stage.
Why is the preproposal stage important?
The preproposal is the gatekeeping step. Since full applications are by invitation only, the preproposal is critical for gaining access to the full application stage.
How many awards does the program expect to make?
The program expects to make about five awards.
What is the estimated total funding available for this opportunity?
The estimated total funding pool is $6,000,000.
Is cost sharing or matching required?
No. Cost sharing or matching funds are not required.
Who is eligible to apply?
Eligibility is described as broadly open (unrestricted) to any type of entity, provided the applicant meets any additional eligibility details included in the full announcement.
What research focus is expected?
The research must revolve around a central, innovative question or problem in prostate cancer and should be designed to produce meaningful advances in understanding, prevention, diagnosis, or treatment strategies.
Does the program allow high-risk or unconventional ideas?
Yes. High-risk concepts are allowed as long as there is a credible possibility of major impact and the rationale is strong.
Are preliminary data required?
No. Preliminary data are encouraged but not required.
If preliminary data are not required, what is still expected from the proposal?
Even without extensive preliminary data, the proposal is expected to be rigorous and persuasive about the innovation, the strength and necessity of the collaboration, and the likelihood that the work could materially advance prostate cancer research or downstream outcomes.
What are the most important review criteria?
The most important review criteria are Synergy, Innovation, and Impact.
What does the review criterion "Innovation" emphasize?
Innovation emphasizes how novel the concepts, hypotheses, methods, or technologies are, including whether the project challenges existing assumptions or opens new pathways in prostate cancer research.
What does the review criterion "Impact" emphasize?
Impact focuses on how likely the project is to significantly advance prostate cancer research or lead to meaningful downstream benefits.
Is incremental research a good fit for this mechanism?
The program signals a preference for research that could "move the needle" in a noticeable way, rather than primarily supporting incremental progress.
Are clinical trials allowed under this award?
No. A major restriction is that the award does not support clinical trials.
What types of studies are appropriate if clinical trials are not allowed?
Appropriate projects include non-clinical-trial research such as preclinical, translational, mechanistic, computational, and biomarker discovery/validation activities, as long as the work is not structured as a clinical trial as defined by the funder.
What should applicants do to avoid proposing a clinical trial?
Applicants should ensure their aims, endpoints, and overall study design do not cross into clinical trial territory as defined by the funder.
When was this opportunity posted?
It was posted on March 20, 2012.
What were the original and final closing dates?
Both the original and final closing date were August 9, 2012.
When was the opportunity archived?
It was archived on September 8, 2012.
Who should be contacted for technical access issues with the full announcement?
For technical access issues, the listed contact is the CDMRP Help Desk at 301-682-5507.
Browse more opportunities from the same category: Science and Technology and other Research and Development
Next opportunity: Coordinating Center for Research and Training to Promote the Health of People with Developmental and Other Disabilities
Previous opportunity: Statement of Interest Trafficking in Persons
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for W81XWH 12 PCRP SIDA
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (W81XWH 12 PCRP SIDA) also looked into and applied for these:
| Funding Opportunity |
|---|
| Scientific Collaborations at Extreme Scale Apply for DE FOA 0000695 Funding Number: DE FOA 0000695 Agency: Office of Science Category: Science and Technology and other Research and Development Funding Amount: $1,000,000 |
| Small Business Innovation Research Program Phase I Solicitation FY 2013 Apply for 12 548 Funding Number: 12 548 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Frontiers in Earth System Dynamics Apply for 12 547 Funding Number: 12 547 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Biologically derived Medicines on Demand (Bio MOD) Apply for DARPA BAA 12 37 Funding Number: DARPA BAA 12 37 Agency: DARPA Defense Sciences Office Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer Collaborative Undergraduate HBCU Student Summer Training Program Award Apply for W81XWH 12 PCRP STPA Funding Number: W81XWH 12 PCRP STPA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer Physician Research Training Award Apply for W81XWH 12 PCRP PRTA Funding Number: W81XWH 12 PCRP PRTA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer Postdoctoral Training Award Apply for W81XWH 12 PCRP PTA Funding Number: W81XWH 12 PCRP PTA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer Health Disparity Research Award Apply for W81XWH 12 PCRP HDRA Funding Number: W81XWH 12 PCRP HDRA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Prostate Cancer Exploration Hypothesis Development Award Apply for W81XWH 12 PCRP EHDA Funding Number: W81XWH 12 PCRP EHDA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD FY12 Neurofibromatosis Exploration Hypothesis Development Award Apply for W81XWH 12 NFRP EHDA Funding Number: W81XWH 12 NFRP EHDA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD FY12 Neurofibromatosis Investigator Initiated Research Award Apply for W81XWH 12 NFRP IIRA Funding Number: W81XWH 12 NFRP IIRA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD FY12 Neurofibromatosis New Investigator Award Apply for W81XWH 12 NFRP NIA Funding Number: W81XWH 12 NFRP NIA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD FY12 Neurofibromatosis Clinical Trial Award Apply for W81XWH 12 NFRP CTA Funding Number: W81XWH 12 NFRP CTA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD FY12 Tuberous Sclerosis Complex Exploration Hypothesis Development Award Apply for W81XWH 12 TSCRP EHDA Funding Number: W81XWH 12 TSCRP EHDA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD FY12 Tuberous Sclerosis Complex Idea Development Award Apply for W81XWH 12 TSCRP IDA Funding Number: W81XWH 12 TSCRP IDA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DOD FY12 Tuberous Sclerosis Complex Clinical Trial Award Apply for W81XWH 12 TSCRP CTA Funding Number: W81XWH 12 TSCRP CTA Agency: Dept. of the Army USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Biophotonics Apply for PD 13 7236 Funding Number: PD 13 7236 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $600,000 |
| Biomedical Engineering Apply for PD 13 5345 Funding Number: PD 13 5345 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $600,000 |
| Biotechnology, Biochemical, and Biomass Engineering Apply for PD 13 1491 Funding Number: PD 13 1491 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: $600,000 |
| Process and Reaction Engineering Apply for PD 13 1403 Funding Number: PD 13 1403 Agency: National Science Foundation Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 12 PCRP SIDA", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.